CA1135260A - Maytansinoids, their production and use - Google Patents

Maytansinoids, their production and use

Info

Publication number
CA1135260A
CA1135260A CA000353518A CA353518A CA1135260A CA 1135260 A CA1135260 A CA 1135260A CA 000353518 A CA000353518 A CA 000353518A CA 353518 A CA353518 A CA 353518A CA 1135260 A CA1135260 A CA 1135260A
Authority
CA
Canada
Prior art keywords
maytansinol
alpha
process according
4alkyl
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000353518A
Other languages
French (fr)
Inventor
Hiroshi Akimoto
Osamu Miyashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of CA1135260A publication Critical patent/CA1135260A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Abstract of the Disclosure Novel maytansinoids of the formula:

Description

i^'''`` ~l~S~

MAYTA~ISrNOIDS, THEIR P~ODDC~I N AND USE
This invention relates to novel maytansinoid ccmpGunds of the formula: y OCOR

~ ~ N (I) lo : -wherein Y is H or Cl, and R is C2_15alkyl, phenyl-Cl_4alkyl, pyridyl-Cl 4aIkyl, imidazolyl-Cl 4alkyl, indolyl-Cl 4aIkyl, furyl-Cl 4alkyl or thienyl-Cl 4alkyl, any of said groups being sub-stituted bv hydroxyl, protected hydroxyl, halogen or Cl 5alkanoyloxy at its ~-carkon atcm or its ~-carbon atcm or koth its ~- and ~-carkon atoms, and to a method for production and use of the ccm-pounds (I).
Ref~rring to the above form~la (I), the C2 15alkyl group may for example be ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decvl, undecyl, dodecyl, tridecyl, tetrad~.cyl, pentadecyl, neopentyl or
2-ethylhexyl. A preferred aIkyl group is C2 10alkyl.
As examples of Cl 4alkyl moieties in the phenyl-Cl 4alkyl and heterwycle-Cl 4aIkyl groups, there may be mentioned methyl, ethyl, propyl, isopropyl, butyl, isobutyl and sec-butyl, preferably methyl and ethyl. Accordingly, - 1 - ~g . , the phenyl-Cl 4alkyl group may for example be benzyl, phenethyl, 1-phenylethyl (~-methylbenzyl), 1- or 2-methyl-2-phenylethylO The pyridyl-Cl 4alkyl group includes 2-,
3- or 4-pyridylmethyl and 2-(2-, 3- or 4-pyridyl)ethyl~
The imidazolyl-Cl 4alkyl group includes imidazolylmethyl and imidazolylethylO The indolyl-Cl 4alkyl group includes indolylmethyl and indolylethyl The furyl-Cl 4alkyl group includes 2 or 3-furfuryl and 2-(2- or ~-furyl)ethylO
~he thienyl-Cl 4alkyl group includes 2- or 3-thenyl and 2-(2- or 3-thienyl)ethyl~
~ he above-mentioned C2 15alkyl, phenyl-Cl_4alkyl and heterocycle-Cl 4alkyl groups have hydroxyl, halogen or Cl 5alkanoylox~ as a substituent or substituents at the ~- and~or ~-positionO Said halogen atom includes chlorine, bromine, iodine and fluorine, and said Cl 5alkanoyloxy group includes formyloxy, acetyloxy, propionyloxy, butyryl-oxy, isobutyryloxy, pentanoyloxy and isopentanoyloxyO
When both of the a- and ~positions are substituted by hydroxyls, said hydroxyls may be protected in the form of acetalO In this specification, the a-position means the adjacent carbon atom in R-groups to the carbonyl group connecting with the hydroxyl group at the 3-position of maytansinol, and the ~-position means the next one to the a-position~
~ he groups designated by R may optionally have suitable substituents at substitutable positions, in addition to the above-mentioned substituent, iOeu hydroxyl, halogen or Cl 5alkanoyloxy at ~- and/or ~-positionO Said substituents include Cl 4alkoxy (eOg methoxy, ethoxy, propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy), Cl 4alkanoyloxy (eOgO formyloxy, acetyloxy, propionyloxy, n-butyryloxy, isobutyryloxy), C2 L~alkoxycarbonyl (eOgO
methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, iso-propoxycarbonyl), halogen (eOgO chlorine, fluorine, bromine, iodine), nitro, cyano, trifluoromethyl, di-Cl 4alkylamino (eOgO dimethylamino, diethylamino, dipropylamino, diiso-propylamino, dibutylamino), Cl 4alkylthio (eOg~ methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert butylthio), Cl 4alkyl-sulfinyl (eOgO methylsulfinyl), Cl 4alkylsulfonyl (eOgO
methylsulfonyl), Cl 4alkanoylamino (eOgO formylamino, acetylaminot propionyla~ino, butyrylamino, isobutyrylamino), sulfamoyl and so onO When R is phenyl-Cl 4alkyl or heterocycle-Cl 4alkyl, in addi-tion to the substituents mentioned ~ust above, there may be mentioned, as substi-tue~nts, Cl 4alkyl (eOgO methyl, ethyl~ n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl) and C2 4alkanoyl (eOgO acetyl, propionyl, n-butyryl, isobutyryl)O These substituents may be the same or different and may tot~l 1 to 3u When hydroxyl, halogen or Cl 5alkanoyloxy at the ~-or ~-position is designated as X and the adjacent carbon ~L3SZ~3 atom to the carbonyl group connecting with the hydroxyl group at the 3-position of maytansinol is defined as the first (1- or ~-) position, examples of the groups R may be mentioned as followsO
~ he relevant ~roups to C2 15alkyl may for example be l-X-ethyl, l-X-propyl~ l-X-butyl, l-X-isobutyl, l-X-pentyl, l-X-isopentyl, l-X-hexyl, l-X-octyl, l-X-nonyl, l-X-decyl, l-X-undecyl, l-X-dodecyl, l-X-tridecyl, l-X-pentadecyl, l-X-l-methylethyl, l-X-l-methylpropyl, l-X-l-methylbutyl, l-X-l-methylisopentyl, 2-X-ethyl, 2-X-propyl, 2-X-butyl, 2-X-l-methylbutyl, 2-X-isopropyl, 2-X-l-ethylethyl, 2-X-pentyl, 2-X-nonyl, 1,2-di-X-ethyl, 1,2-di-X-l-methylethyl and 1,2-di-X-propylO As examples of further substituted groups, there may be mentioned l-X-3-methylthiopropyl, l-X-3-ethylthiopropyl, 1-X-3-methylsulfinylpropyl, 1-X-3-methylsulfonylpropyl, l-X-2-methoxyethyl, 1-X-3-ethoxy-carbonylpropyl, l-X-2-ethoxycarbonylethyl and 2-X-3-ethoxycarbonylpropyl O
~ he relevant groups to phenyl-Cl 4alkyl may for example be a-X-benzyl, l-X-2-phenylethyl, a~ -methylbenzyl, l-X-l-methyl-2-phenylethyl and 2-X-l-phenylethylO As e~amples of further substituted groups, there may be mentioned groups formed by replacing the phenyl in the above groups ~ith a substi-tuted phenyl such as 2- t 3- or
4-methylphenyl, 4-ethylphenyl, 2-, 3- or 4-chlorophenyl, : 3- or 4-bromophenyl, 3- or 4-fluorophenyl, 2,4- or 3,4-" ~

dichlorophenyl, 2-, 3- or 4-methoxyphenyl, 2,5- or ~,4-dimethoxyphenyl, 4-hydroxyphenyl, 4-acetoxyphenyl, 4-butoxyphenyl, 4-iodophenyl, 3- or 4-trifluoromethylphenyl, 2- or 4-nitrophenyl, 4-cyanophenyl, 4-methanesulfonylamino-phenyl, 2-chloro-4-methoxyphenyl, 2-chloro-5-methylphenyl, 2,4,6-trimethylphenyl or 3,4,5-trimethoxyphenylO
~ he rele~ant groups to indolyl-Cl 4alkyl may for example be l-X-l-(3-indolyl)methyl and 1-X-2-(3-indolyl) ethyl, and further substituted groups may for example be l-X-2-(5-chloro-3-indolyl)ethyl and 1-X-2-(5-hydroxy-3-indolyl)ethyl~
~ he relevant groups to imidazolyl-Cl 4alkyl may for example be l-X-2-(4(5)-imidazolyl)ethyl and 1-X-2 methyl-4-imida7.olyl)ethyl a ~ he relevant groups to furyl-Cl 4~1~y1 may for example be l-X-1-(2-furyl)methyl, 1-X-1-(3-furyl)methyl~ 1-X-2-(2-furyl)ethyl and l-X-2-(3-furyl)ethyl, and further substi-tuted groups may for example be l-X-1-(5-methyl-2-furyl)-methyl, l-X-1-(5-methoxycarbonyl-2-furyl)methyl, l-X-l-(5-nitro-2~furyl)methyl and 1-X-2-(5-ethoxycarbonyl-2-furyl)ethyl a The relevant groups to thienyl-Cl 4alk~1 ~ay for example be l-X-1-(2-thienyl)methyl, 1-X-1-(2-thienyl)ethyl, l-X-l-(3-thienyl)methyl~ 1-X-2-~2-thienyl)ethyl and 1-X-2-(3-thienyl)ethyl, and further substituted groups may for example be 3- or 5-methyl-1-X-1-(2-thienyl)ethyl and 1-X-1-(3,5-dimethyl-2-thienyl)methylO

The relevant groups to pyridyl-Cl 4alkyl may for example be l-X-1-(2-, 3- or 4-pyridyl)methyl, 1-X-2-(2-, 3- or 4-pyridyl)ethyl and 1,2-di-X-2-(3-pyridyl)ethyl, and further substituted groups may for example be l-X-2-(6-methyl-2-pyridyl)ethyl and 1-X-2-(2,6-dichloro-~-pyridyl)ethylO
The maytansinoid compound (I) of the present invention can be produced by acylating maytansinol or dechloro-maytansinol of the formula:

Co~3 (II) N ~ O

CH~ CH30 wherein Y is as defined above, with a carboxylic acid of the formula:
RCOOH (III) wherein R is as defined above, or its reactive derivative with respect to the carboxyl function thereofO
An exemplary reaction procedure comprises acylatin~
a compound (II) with a carboxylic acid (III) in the presence of a carbodiimide~ Based on compound (II), carboxylic acid (II~) may be used in an amount of, for example, about 1 to 50 molar equivalents a~d, in many cases, is preferably employed in an amount of about 1 - 20 molar equivalents.
The carbodiimide may be used in an amount of about 1 to 70 molar equivalen-ts based on compound (II) and, in many cases7 is preferably employed in an amount of abou-t 1 - 30 molar equivalentsO
~ he usable carbodiimide is preferably dicyclohexyl-carbodiimide, although such other carbodiimides may also be employed as, for example, diphenylcarbodiimide, di-o-tolylcarbodiimide, di-p-tolylcarbodiimide, di-tert-butyl-carbodii~ide, l-cyclohexyl-3-(2-morpholinoethyl)carbodiimide, l-cyclohexyl-~-(4-diethylaminocyclohexyl)carbodiimide, l-ethyl-3-(2-diethylaminopropyl)carbodiimide and 1-ethyl-3-(3-dimeth.ylaminopropyl)carbodiimideO
~ his acylation reaction may be carried out in a suitable solventO Examples of such solvent include esters (eOgO ethyl acetate), ethers (eOgO diethyl ether, dioxane, tetrahydrofuran), halogenated hydrocarbons (e gO methylene chloride, chloroform), nitriles (eOgO acetonitrile~, aromatic hydrocarbons (eOgO benzene), nitromethane, pyridine, dimethylformamide, dimethylsulfoxide, sulfolane, etcO, as well as appropria-te mixtures of such solventsO
~ his reaction may be usually carried out at a suitable temperature from ice-cooling to the re~lux point of the reaction systemO

This acylation reaction can be advantageously hastened wi~h the aid of a catalyst capable of promoting acylation of compoun~ (II). The catalyst may be an appropriate acid or baseO The basic catalyst includes, among others, tertiary amine compounds (e~gO aliphatic tertiary amines such as triethylamine; aromatic tertiary amines such as pyridine, ~ , or ~-picoline, 2,6-lu-tidine, 4-dimethyl-aminopyridine, 4-(1-pyrrolidinyl)pyridine, dimethylaniline, diethylaniline), halogenated a].kali metals (eOgO potassium fluoride, anhydrous lithium iodide), salts of organic acids (eOgO sodium acetate) and so forthO The acid catalyst includes, among others, Lewis acids [eOgO anhydrous zinc chloride, anhydrous aluminum chloride (AlC13), anhydrous ferric chloride, titanium tetrachloride (TiC14), stannic tetrachloride (SnC14), antimony pentachloride, cobalt chloride, cupric chloride, boron tri.fluoride etherate, etcO], in.organic strong acids (eOgO sulfuric acid, per-chloric acid, hydrochloric acid, hydrobromic acid, etcO), organic strong acids (eOgO benzenesulfonic acid, p-toluenesulfonic acid, trifluoroacetic acid, trichloroacetic acid, etcO), acidic ion exchange resins (e D gO polystyrene-sulfonic acid), etcO The catalyst is used in a catalytic amount sufficient to promote acylation, for example, about OoOl to about 10 molar equivalents, preferably about OoOl to about 1 equivalent, based on carboxylic acid (III)o The use of such a catalyst leads in many cases to re-markably i~proved yields of maytansinoid compound (I)D

In connection wi-th this reaction, if the carbo~yli~
acid (III) is isomeric, iOeO D- and L-isomers, such isomers may be employed either independently or as an optional mixtureO When compound (I) having an optically active acyl group is desired, the use of the corresponding optical form of carboxylic acid (III) proves advantageous in some instances ~here also are cases in which even the use of an optically active carboxylic acid (III) gives rise to a mixture of D- and L-isomers of maytansinoid compound (I)o The acylation process utilizing a reactive derivative o~ carboxylic acid (III) with respect to its carboxyl function may for example be a process which comprises using a derivative having a func-tional group capable o~
acylating the 3-position of compound (II) such as the acid anhydride (and mixed acid anhydride cyclized through a-OH
and carbonic acid) of carboxylic acid (III). The solvent and catalyst ~or use in this acylation reac-tion may be the same as those mentioned hereinbefore in connection with acylation in -the presence of a carbodiimideO The reaction temperature may usually range from about -20C to about +100C and preferably a~out 20C to about 40Co The reaction may be hastened by heating the reaction system to a s-till higher temperatureO
In the above-mentioned acylation, when a sensitive group (eOgO hydroxyl) which reacts with the acylating agent exists in carboxylic acid (III), said group m~y be protected in advance by a suitable protective group ~eOgO a protecti~Je group in -the form o~ ester: lower alkanoyl (e~g~ form~l, acetyl), hologenated lower alkanoyl (e.g~ trifluoroacetyl, trichloroacetyl, chloroacetyl, bromoacetyl, iodoacetyl) or acyl derived from carbonic acid (eOg~ -tert-butyloxycarbonyl, phenoxycarbonyl); a protective group in the form of ether:
benzyl, di.phenylmethyl, triphenylmethyl or p-me-thoxybenzyl], and after the acylation, the protected compound is subjected to a reaction for removal of the protective group to obtain the contemplated compound (I)o The maytansinoid compound (I) thus produced by the above-mentioned acylation can be isolated by subjecting the reaction mixture to a conventional procedure such as concentration, solvent extraction, chromatography, re-crystalliza-tion, etcO When maytansinoid compound (I) is produced as a mixture o~ isomers (eOgO D- and L-isomers), the isomers can be separated from each other generally by a conventional procedure, eOgO silica gel column chromato-graphyO The maytansinoid compound (I) according to this invention includes such individual isomers and all mixtures o~ the isomersO
The maytansinoid compound (I) according to this invention has strong antimitotic and antitumor activities with comparatively low toxicity and are therefore suited fo~ administration, oral or parenterally, to tumor-bearing warm-blooded animals (eOgO mouse, rat, rabbit, dog, cat and man) for the purpose of prolonging their survival ti~es~
Each compound (I) is normally administered in the form of a pharmaceutical preparation (eDg injectable solution) as formulated wi-th a carrier, diluent or -the like which is kno~n per seO
When cor~pound (I) i5 adminis-tered in the form of an injectable preparation, it may be given subcutaneously, intraperi-toneally, intravenously or intramuscularly, for instanceO The dosage of compound (I) varies with the kind, symptom, administration route, etc~ but, for example, in case of intravenous adminis-tra-tion for prolonging life span of the animal suffering from leukemia or melanoma, it may be decided from the range of about 1 to 1000 ~g/kg body weight, preferably about 10 to 500 ~g/kg body weight, especially about 10 to 200 ~g/kg body weight, per dose~
The injectable preparation can be prepared by the established pharmaceutical procedure; for example by dis-solving about 50 ~g to 3 mg of compound (I) in each about 0~5 ml of alcohol (eOg. ethanol), followed by addition of a sufficient amount of physiological saline to make a total of 10 mlO When a small dosage is indicated, the above solution may be further diluted with physiological saline~
The maytansinoid compounds (I) according to this invention are of value also in that they have antimicrobial activity, eOgO antifungal and antiprotozoal propertiesO
~hus, for example, the maytansinoid compounds (I) are ~s~

useful for tre~ting tetrahymena E~ wO As an antifungal or an-tiprotozoal agen-t1 compound (I) is instrumental in assays of the bacterial flora of soil, active sludge, animal body fluids, etc~ q'hus, for the isolation of useful bacteria from soil samples or in the assay of activity of bacteria to -the exclusion of those of protozoa and fungi in connecti.on with the operation and anal~sis of active sludge systems for waste water treat-ment, the compound (I) can be advantageously employed to ensure selective growth of bacteria without permitting growth of the concomitant protozoa and fungiO ~hus, such a sample is added to a liquid or solid medium, and per milliliter of the inoculated medium, Ool ml of a 1 %
methanol-water solution of about 10 to 100 ~g/ml of compound (I) is added, and then incubated to let the bacteria grow and multiplyO
The maytansinoid compound (I), in an amount of 0002 ml of a 1 mg/ml aqueous solution, is able to inhibit growth of causative microorganisms of stem rot J helminthosporium leaf rot and sheath blight in rice plants, for instance, and can therefore be used for the treatment of such plant diseasesO The procedure may comprise dissolving compound (I) in 1 % aqueous methanol to a concentration of about 005 to 5 ~g/ml and spraying rice plants with the solution.
The following reference example and working examples are in-tended to descri.be this invention in further detail and not -to limit its scopeO

Reference Example ln 800 m~ of dry tetrahydrofuran (TH~?) is dissolved 15~0 g of antibiotic Ansami-tocin mixture (12 % of ansamitocin P-2, 71 % of P-3 and 17 % of P-4) and under dF~ ni-trogen gas streams, the solution is cooled -to -50C in a dry ice-acetone bathO 'rhen, 13~0 g of lithium aluminum hydride (~AH) is added in a single dose and -the mixture is stirred at -50~ to -22C for 2 hoursO ~hen, at -28C, a :further 3 g of L~ is added and -the reaction mixture is s-tirred at -28C to 22C for 80 minu-tesO Thereafter, at -50C, 750 m~ of 2N HC~ is added dropwise with caution and the reaction mixture is extracted three times with 206 ~, 106 e and 008 ,e portions of ethyl acetateO The extracts are pooled, washed with a saturated aqueous solution of sodium chloride (100 me x 2) and d:ried (MgS04, 250 g).
'~he solvent is distilled off under reduced pressure and the residue (1306 g) is chromatographed on a column o:f silica gel (102 kg), elution being carried out with ethyl acetate-water (9805: 105, V/V)0 ~he eluate is collected in 400-gram fractionsO ~ractions 35 through 52 are pooled, the solvent distilled off and the residue dried in vacuo to obtain 7025 g of maytansinolO ~hen~ fractions 53 through 68 are similarly treated to obtain 1055 g of a substantially equimolar mixture of maytansinol and dechloromaytansinolO
Similarly, fractions 69 through 86 yield 0078 g of dechloro-maytansinolO

This product is reprecipitated from chloroform-hexane to obtain 007l g of dechloromaytansinolO
m~pO 174-179C (decompnO ) NMR spectrum (CDC13) ~ ppm: 00~6(3H, s), 1~27(3H, d, J=caO 6Hz)~ 1065(3H, s), 2063(1H, d, J=9Hz), 9007(1H, d, J=13Hz), 3~23(3H, s), 3035(3H, s), 3042(1H, d, J=13T~z), 3075(1H, d, J=9Hz), 3031(3H, s), 4037(1H, m), 5.51(1H, dd, J-9Hz & 15Hz), 6010(1H, d, J=llHz), 6041(1H, dd, J=llHz &
15Hz), 6056(1H, d, J=2Hz), 6060(1H, s), 6070(1H, approxO s), 6097(1H, approx. s), Mass spectrum (m/e): 469, etc~
UV spectrum (~mMeaxH) nm: 23105, 24105, 250.5, 27705, Example 1 In 10 ml of dry dichloromethane are dissolved 56~4 mg of maytansinol, 14408 mg of 0-trifluoroacetyl-DL-mandelic acid, 123~6 mg of dicyclohexylcarbodiimide (DCC) and 2504 mg of 4-dimethylaminopyridine (DMAP), and the solution is stirred at room tempera-tureO After the reaction is completed, 1 ml of a saturated a~ueous solution of sodium hydrogen carbonate i.s added and the mixture is stirred at room temperature for about 30 minutesO l'he organic layer is separated and the water layer extracted twice with 5 ml portions of chloroformO The organic layers are combined and dried~ Then, the solvent is dis-tilled off under reduced -- l L~ --' - .

pressure, and the residue is fractionated and purified by silica gel column chromatographyO By this procedure are obtained two diastereoisomers of maytansinol 3-u-hydro~y-phenylacetate with repsect to the center of asymmetry in the mandelic ester moietyO ~raction I (24 mg, first-emerging fraction); Fraction II (9 mg, later-emerging fraction)O TLC (silica gel; Merck, HPTLC) (solvent: CHC~3-MeOH-95:5): Fraction I, Rf=OoL~4; Fraction II, Rf=0031 Mass spectrum (m/e3: Fraction I, 637 (M+ - 61), 485;
Fraction II, 637 (M~ - 61), 485~

Exarn~le 2 As in Example 1, 200 mg of maytansinol, 306 mg of 2,2-dimethyl-1,3-dioxolan-4-carboxylic acid, 438 mg of DCC
and 90 mg of DMAP are reacted in 15 ml of dry dichloromethane~
The reaction mixture is chromatographed on a column of silica gel using a solvent mixture of chloroform-me-thanol (50 1)o ~his procedure yields two diastereoisomers, with respect to the center of asymmetry in the side chain of maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylateO
Fraction I (111 mg, first-emerging fraction); Fraction II
(30 mg, later-emerging fraction)O T~C (silica gel, Merck, HPT~C): ~raction I, Rf=0053; Fraction II, Rf=0046 (solvent:
chloroform-methanol - 95:5)0 Mass spectrum (m/e); ~raction I, 631 (M+ - 61), 616, 485; Fraction II, 631 (M+ - 61), 6160 ~L3~

Example 3 Of the two diastereoisomers of maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylate o~tainable from maytansinol and 2,2-dimethyl-1,3-dioxolan-4-carboxylate, the fraction having a higher Rf value (Frac-tio~ I) on TLC
(sillca gel, Merck, HPTLC; solvent: chloroform methanol =
95:5) is taken and a 84 mg portion thereof is heated in 2 ml of 70 % a~ueous acetic acid at 60C for about 10 hoursO
The reaction mixture is concentrated to dryness under reduced pressure and the residue is chromatographed on a silica gel column (solvent: acetonitrile-water = 95:5)0 By this procedure is obtained 70 mg of maytansinol 3-(2,3-dihydroxy)propionate (one of diastereoisomers)0 Silica gel TLC (Merck, HPTLC): Rf = 0~50 (solven-t = acetonitrile-water - 95:5); Mass spectrum (m/e): 591 (M+ - 61), 576, By the same procedure as above, 16 mg of the fraction having a lower Rf value (~raction II) was reacted and treated to obtain 8 mg of maytansinol 3-(2,3-dihydroxy) propionate (the other dias-tereoisomer)0 Silica gel ~LC
(Merc~, HPTLC): R~ = 0042 (solvent: acetonitrile-water =
95:5)0 Mass spectrum (m/e): 591 (1~ - 61), 576, 5030 Example 4 In 5 ml of dry dichloromethane are dissolved 108 mg of maytansinol, 257 mg of L-0-acetylmandelic acid and 241 mg of DCC and the mixture is stirred at room temperature for , about 10 ~.inutes. Then, 4807 mg of DMAP is added ar.d stirred at room temperature for an hourO The in.solubles are filtered off, the filtrate concentrated to dryness under reduced pressure and the residue di.ssolved in ethyl acetater The solution is washed with lN-hydrochloric acid, water, saturated aqueous sodium hydrogen carbonate and water in the order men-tionedO The organic layer is taken and dried (over Na2S04) ~nd the solvent is distilled off under reduced pressureO The residue is chromatographed on 75 g silica gel (solvent: ethyl acetate) and the eluate is collected in 15-gram fractionsO Fractions 31 t'nrough 48 are combined and evaporated, whereby 280 5 mg of maytansinol 3-(~-acetoxyphenyl)acetate, which is considered to be one of diastereoisomers with respec-t to the center of asymmetry in ~he si~e c~ , 7 ~ ~tai~d ~ 7 t~ g~7 7 d~
mOp. 177-181C (decompnO) (as recrystallized ~rom ethyl ace-tate-ether) W spectrum ( ~mMaH (nm): 233, 241 (sh), 28105, 28905 Mass ~pectrum (m/e); 679 (M+ - 61) Example 5 In 5 ml of dry dichloromethane are dissolved 100 mg of maytansinol, 221 mg of DL~0-acetyltropic acid and 255 mg of DCC and the mixture is stirred at room temperatureO
After abou-t 5 minu-tes, 64o8 m~ of DI~AP is added and stirred at room temperature overnightO The insolubles are filtered off and the dichloromethane la~er is washed with lN HCR, S~

a satura-t~d aqueous solution of sodium hydrogen carbonate and ~ater in the order mentioned, followed by drying over Na2S04.. Tne solvent is then distilled off, the residue dissolved in ethyl acetate and the insolubles filtered off~
~he filtrate is chromatographed on silica gel (30 g) (solvent = ethyl acetate: water-saturated ethyl acetate =
3:1, v/v) and the eluate is collected in 15-gram fractionsO
~ractions 9 through 13 are combined and evaporated, and the residue rechromatograph.ed on silica gel (30 g) (solvent =
chloroform-methanol = 40:1, v/v), the eluate being collected in 25-gram fractionsO Fractions 5 through 8 are combined and evaporated to give 908 mg of maytansinol 3-~-ace-toxy-methylphenylacetate (one of isomers)O
UV spectrum (~ mMexH (nm)): 232, 24205(sh), 252, 281, 290;
Mass spectrum (m/e): 693 In the first chromatographic run mentioned above, fractions 14 through 21 are combined and evaporated to give 1206 mg of maytansinol 3-~-acetoxymethylphenylacetateO
UV spectrum (~ mMaxH (nm)): 233, 242(sh), 25205, 281, 289;
Mass spectrum (m/e): 693 Exam~le_6 As in Example 1, 130 mg of maytansinol, as a starting ma-terial, 23508 mg of ~-chlorophenylacetic acid, 6102 mg of DMAP and 28409 mg of DCC are reacted in 15 ml of dry ; - 18 -l~L3~jz~jo dichloromethaneO After the reaction has ~een completed, the dicyclohexylurea is filtered off and the filtrate is purified ~y silica gel column chromatography (ethyl acetate:
water-satura-ted ethyl acetate = 9 1)o By this procedure are obtained two diastereoi.somers of may-tansinol 3-~-chlorophenylace-tate with respec-t to the ~-chlorophenyl-acetate moietyO Fraction I (23 mg, first-emerging fraction), Fraction II (~5 mg, later-emergi.ng fraction)0 Silica gel TLC (Merck, HPT~C; developing solvent: chloroform-methanol =
95:5): Fraction I, R~ = 0067; Fraction II, Rf = 00590 Mass spectrum (m/e): ~raction I, 655 (M+ - 61); Fraction II, 655 (M+ - 61)o ~Z
In 5 ml of dichloromethane are dissolved 5304 mg of dechloromaytansinol, 135 mg of 0-acetyl-D-mandelic acid and 129 mg of DCC and the mixture is stirred at room temperature for 5 minutesO Then, 44 mg of DMAP is added and the mixture stirred at room -temperature for an hourO
The insolubles are filtered off, the filtrate concentrated to dryness under reduced pressure and the residue extracted with ethyl acetateO The extract is fractionally purified by silica gel chromatography (silica gel 45 g; solvent =
ethyl acetate: H20-saturated e-Ehyl acetate = 6:1, v/v)0 By the above procedure is obtained 1502 mg of dechloro-maytansinol ~ acetoxyphenylacetate (which is considered to be one of diastereoisomers with respect to the center of asymmetry in -the side chain)0 Sili.ca gel TLC (Merck, HPTLC; solvent: e-thyl aceta-te): ~f = 0029 Mass .spectrum (m/e); 6~5 (M-~ - 61)o Experimen-tal Data Antitumor ac-tivity Therapeutic tests were carried out in mice according to NCl-protocol 1,300, Cancer Chemother, Reports, Part 3, 1972, VolO ~, NoO2, in which melanoma B-16 tumor cells had been intraperitoneally -transplanted, compound (I) being administered intraperitoneally once daily for 9 consecutive daysO Li~e span prolongations obtained are shown in ~able 1 as T/C % valuesO

Table 1 Antitumor Dose ac-tivities Compound (~g/kg) B~16 ~ _ (T/C%) Maytansinol 1205 161 3-~-acetoxyphenylacetate 6025 260 301~5 1~1 Maytansinol 800 217 3-~-hydroxyphenylace-tate 400 247 (Fraction 1) 200 208 ; ~ - 20 -~3S~

Antiprotozoal activity Antiprotozoal activity of compound (I) was assayed with Tetrah,ymena pyriformis W as the tes-t organism and a medium composed of 20 g tryptose-peptone (Difco CoO), l g yeast extract, 2 g glucose, lO00 ml dis-tilled water, lO ml lM phosphate buffer (pH 7O0) as the assay mediurn. The microorga~ism was incubated at 28C for 44 to 48 hours and the growth inhibitory activity of compound (I) was assayed by the serial dilution method. The minimal inhibitory concentrations of compound (I) are shown in Table 2 Table 2 .
Antiprotozoal activity Compound MIC (~g/ml) Tetrahymena pyriformis W

Maytansinol 3-~-acetoxyphenylacetate < 2 Maytansinol 3-~-acetoxyme-thyl-phenylacetate 1 - 2 (from fractions 9-13 of the 1st chromato-graphy) Examples of Pharmaceutical_Composition_ Example A

Composition for Injection (1) Maytansinol 3-a-acetoxyphenylacetate 50 mg (2) ~thanol 10 g ~) Polysorbate 80 (Tween 80) 40 g (4) Mannitol 20 g
(5) Distilled water, a sufficient quantity to make lC00 ml Preparation (1) is dissolved in (2)o To this solution, (3) and (4) are added, followed by the addition of sterilized distilled water to make 1000 ml of the solutionO Ten milliliter each of the solution is used to fill 100 amber ampoules and the air within the ampoules is replaced with nitrogen gas, then the ampoule is sealedO All the processes are conducted under sterile conditionsO

Example B
Composition for Injection (1) Maytansinol 3-a~hydroxyphenylacetate (Frac-tion I) 200 mg --(2) E-thanol 5 g : (3) Polysorbate 80 (Tween 80) 100 g (4) Mannitol 20 g (5) Distilled water, a sufficient quantity to make 1000 ml : Preparation By a similar procedure to that of ~xample A, an injectable solution of (1) is preparedO

Claims (28)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for preparing a compound of the formula:

I

wherein Y is H or C1, and R is C1-15alkyl, phenyl-C1-4alkyl, pyridyl C1-4 alkyl, imidazolyl-C1-4alkyl, indolyl-C1-4alkyl, furyl-C1-4alkyl or thienyl-C1-4alkyl, any of said groups being substituted by hydroxyl, protected hydroxyl, halogen or C1-5alkanoyloxy at its .alpha.-carbon atom or its .beta.-carbon atom or both its .alpha.- and .beta.-carbon atoms, which process comprises acylating maytansinol or dechloromaytansinol of the formula II

II

wherein Y is as defined above, with a carboxylic acid of the formula:

RCOOH III
wherein R is as defined above, or its reactive derivative with respect to the carboxyl function thereof.
2. A process according to claim 1 wherein the group R is substituted on both its .alpha.- and .beta.-carbon atoms by hydroxyl groups which are protected in the form of an acetal.
3. A process according to claim 1 or 2 wherein Y is C1.
4. A process according to claim 1, 2 or 3 wherein R is C2-15 alkyl or phenyl-Cl 4 alkyl, said groups being substituted by hydroxyl, protected hydroxyl, halogen or C1-5 alkanoyloxy at its .alpha.-carbon atom or its .beta.-carbon atom or both its .alpha.- and .beta.-carbon atoms.
5. A process according to claim 1, 2 or 3 wherein the acylation is carried out in the presence of a carbodiimide.
6. A process according to claim 1, 2 or 3 wherein the acylation is carried out in the presence of about 1 to 30 molar equivalents, based on the compound of formula II, of dicyclohexylcarbodiimide.
7. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is .alpha.-hydroxybenzyl.
8. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is (2,2-dimethyl)-1,3-dioxolan-4-yl.
9. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is 1,2-dihydroxy-ethyl.
10. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is .alpha.-acetoxybenzyl.
11. A process acoording to claim 1, 2 or 3 wherein Y is chlorine and R is .alpha.-acetoxyme-thylbenzyl.
12. A process according to claim 1, 2 or 3 wherein Y is chlorine and R is .alpha.-chlorobenzyl.
13. A process according to claim 1, 2 or 3 wherein Y is hydrogen and R is .alpha.-acetoxybenzyl.
14. Compounds of formula I as defined in claim 1 when prepared by a process according to claim 1 or an obvious chemical equivalent thereof.
15. A process for preparing maytansinol 3-.alpha.-hydroxyphenylacetate which comprises reacting maytansinol with 0-trifluoroacetyl-DL-mandelic acid.
16. Maytansinol 3-.alpha.-hydroxyphenylacetate when prepared by a process according to claim 15 or an obvious chemical equivalent thereof.
17. A process for preparing maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylate which comprises reacting maytansinol with 2,2-dimethyl-1,3-dioxolan-4-carboxylic acid.
18. Maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylate when prepared by a process according to claim 17 or an obvious chemical equivalent thereof.
19. A process according to claim 17 which includes the further step of reacting the maytansinol 3-(2,2-dimethyl)-1,3-dioxolan-4-carboxylate with acetic acid to obtain maytansinol 3-(2,3-dihydroxypropionate.
20. Maytansinol 3-(2,3-dihydroxy)propionate when prepared by a process according to claim 19 or an obvious chemical equivalent thereof.
21. A process for preparing maytansinol 3-.alpha.-acetoxyphenylacetate which comprises reacting maytansinol with 0-acetylmandelic acid.
22. Maytansinol 3-.alpha.-acetoxyphenylacetate when prepared by a process according to claim 21 or an obvious chemical equivalent thereof.
23. A process for preparing maytansinol 3-.alpha.-acetoxymethylphenylacetate which comprises reacting maytansinol with O-acetyltropic acid.
24. Maytansinol 3-.alpha.-acetoxymethylphenylacetate when prepared by a process according to claim 23 or an obvious chemical equivalent thereof.
25. A process for preparing maytansinol 3-.alpha.-chlorophenylacetate which comprises reacting maytansinol with .alpha.-chlorophenylacetic acid.
26. Maytansinol 3-.alpha.-chlorophenylacetate when prepared by a process according to claim 25 or an obvious chemical equivalent thereof.
27. A process for preparing dechloromaytansinol 3-.alpha.-acetoxyphenyl-acetate which comprises reacting dechloromaytansinol with O-acetyl mandelic acid.
28. Dechloromaytansinol 3-.alpha.-acetoxyphenylacetate when prepared by a process according to claim 27 or an obvious chemical equivalent thereof.
CA000353518A 1979-06-08 1980-06-06 Maytansinoids, their production and use Expired CA1135260A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP72811/1979 1979-06-08
JP7281179A JPS55164685A (en) 1979-06-08 1979-06-08 Novel maytansinoid compound and its preparation

Publications (1)

Publication Number Publication Date
CA1135260A true CA1135260A (en) 1982-11-09

Family

ID=13500153

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000353518A Expired CA1135260A (en) 1979-06-08 1980-06-06 Maytansinoids, their production and use

Country Status (6)

Country Link
US (1) US4317821A (en)
EP (1) EP0021178B1 (en)
JP (1) JPS55164685A (en)
AT (1) ATE5885T1 (en)
CA (1) CA1135260A (en)
DE (1) DE3066149D1 (en)

Families Citing this family (271)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
PL213213B1 (en) 1999-06-25 2013-01-31 Genentech Inc METHODS OF TREATMENT USING ANTI−ErbB ANTIBODY−MAYTANSINOID CONJUGATES
JP4776843B2 (en) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド Cancer composition and method using immunoconjugate and chemotherapeutic agent
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT1392359E (en) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
DK2000545T3 (en) 2001-06-20 2011-11-28 Genentech Inc Compositions and methods for diagnosis and treatment of lung tumor
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
EP2174953A1 (en) 2001-09-18 2010-04-14 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005536190A (en) 2002-04-16 2005-12-02 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
EP1633784B1 (en) 2003-05-09 2011-07-13 Diadexus, Inc. Ovr110 antibody compositions and methods of use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
CR20170291A (en) 2003-05-20 2017-07-27 Immunogen Inc IMPROVED CYTOTOXIC AGENTS UNDERSTANDING NEW MAITANSINÓIDES
KR101581040B1 (en) 2003-06-27 2015-12-30 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
JP2007501011A (en) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド Binding polypeptide having restriction diversity sequence
ES2493016T3 (en) 2003-11-17 2014-09-11 Genentech, Inc. Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or a cytotoxic agent and methods for the treatment of tumors of hematopoietic origin
PT1718677E (en) 2003-12-19 2012-07-18 Genentech Inc Monovalent antibody fragments useful as therapeutics
NZ551180A (en) * 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
EP2361931B1 (en) 2004-07-20 2017-12-06 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
CN101023182B (en) 2004-07-26 2013-04-17 健泰科生物技术公司 Methods and compositions for modulating hepatocyte growth factor activation
AU2004224925C1 (en) * 2004-08-30 2011-07-21 Biotest Ag Immunoconjugates targeting syndecan-1 expressing cells and use thereof
HUE058817T2 (en) * 2004-09-03 2022-09-28 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
ES2343746T3 (en) 2005-01-07 2010-08-09 Diadexus, Inc. OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE.
US7301019B2 (en) * 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
EP1871163A2 (en) 2005-06-06 2008-01-02 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
WO2007021423A2 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ES2577292T3 (en) 2005-11-07 2016-07-14 Genentech, Inc. Binding polypeptides with diversified VH / VL hypervariable sequences and consensus
JP2009516514A (en) 2005-11-21 2009-04-23 ジェネンテック・インコーポレーテッド Novel gene disruptions, compositions and methods related thereto
ES2547689T3 (en) 2005-12-02 2015-10-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling that involve antibodies that bind to IL-22 and IL-22R
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
RU2470941C2 (en) * 2005-12-02 2012-12-27 Дженентек, Инк. Binding polypeptides and use thereof
KR101538521B1 (en) 2005-12-15 2015-07-22 제넨테크, 인크. Methods and compositions for targeting polyubiquitin
BRPI0706840A2 (en) 2006-01-05 2011-04-05 Genentech Inc polynucleotide isolated anti-ephb4 antibodies, vector, host cell, method for producing an anti ephb4 antibody, method for producing an anti ephb4 immunoconjugate, method for detecting ephb4, method for diagnosing a composition disorder, method for inhibiting angiogenesis, method for treating a cancer, tumor and / or cell proliferation disorder and use of an antibody
CN101410413B (en) 2006-01-20 2013-04-24 健泰科生物技术公司 Anti-EPHRINB2 antiboies and methods using same
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
AR059851A1 (en) 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2010662A2 (en) 2006-04-19 2009-01-07 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
KR101454508B1 (en) 2006-05-30 2014-11-04 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
JP2010503407A (en) 2006-09-12 2010-02-04 ジェネンテック・インコーポレーテッド Methods and compositions for diagnosis and treatment of cancer
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
EP2104513B1 (en) 2006-11-27 2015-05-20 diaDexus, Inc. Ovr110 antibody compositions and methods of use
MX338185B (en) * 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Use of anti-egfr antibodies in treatment of egfr mutant mediated disease.
US7834154B2 (en) 2007-02-09 2010-11-16 Genentech, Inc. Anti-ROBO4 antibodies and uses therefor
JP5618549B2 (en) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Method of treatment using EGFR antibody and SRC inhibitor and related preparation
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
PE20090321A1 (en) 2007-06-04 2009-04-20 Genentech Inc ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION
DK2474557T3 (en) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
ES2528922T3 (en) 2007-07-16 2015-02-13 Genentech, Inc. Humanized and immunoconjugate anti-CD79b antibodies and methods of use
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
US20110033476A1 (en) * 2007-11-12 2011-02-10 Theraclone Sciences Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2220116B1 (en) * 2007-11-12 2012-09-05 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
TWI580694B (en) 2007-11-30 2017-05-01 建南德克公司 Anti-vegf antibodies
CA2710483C (en) * 2007-12-26 2018-05-08 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
MX2010007102A (en) * 2007-12-26 2011-07-01 Biotest Ag Immunoconjugates targeting cd138 and uses thereof.
WO2009080831A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
PL2238168T3 (en) * 2007-12-26 2014-11-28 Biotest Ag Agents targeting cd138 and uses thereof
WO2009126350A2 (en) 2008-01-18 2009-10-15 Genentech, Inc. Methods and compositions for targeting polyubiquitin
AU2009210636B2 (en) 2008-01-31 2014-08-28 Genentech, Inc. Anti-CD79b antibodies and immunoconjugates and methods of use
MX2010009885A (en) 2008-03-10 2010-11-30 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of cytomegalovirus infections.
DK2254571T3 (en) 2008-03-18 2015-09-28 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and the chemotherapeutic agents and methods of using
PL2279412T3 (en) 2008-04-09 2017-12-29 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
PL2279004T3 (en) * 2008-05-16 2015-06-30 Hoffmann La Roche Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
DK2318832T3 (en) 2008-07-15 2014-01-20 Academia Sinica Glycan arrays on PTFE-like aluminum coated slides and related methods
ES2541726T3 (en) 2008-10-01 2015-07-23 F. Hoffmann-La Roche Ag Anti-Notch2 antibodies and methods of use
KR20110101212A (en) 2008-12-17 2011-09-15 제넨테크, 인크. Hepatitis c virus combination therapy
SI3260136T1 (en) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv) -neutralizing antibodies
TW201438739A (en) 2009-03-20 2014-10-16 Genentech Inc Anti-HER antibodies
BRPI1006448B1 (en) * 2009-03-25 2021-08-17 Genentech, Inc ANTI-FGFR3 ANTAGONIST ANTIBODY, MONOCLONAL ANTIBODY, POLYNUCLEOTIDE, VECTOR, TRANSGENIC MICROORGANISM, METHOD FOR THE PRODUCTION OF AN ANTI-FGFR3 ANTIBODY, PHARMACEUTICAL FORMULATION AND USES OF ANTI-FR3 ANTAGONIST ANTIBODY
WO2010120561A1 (en) 2009-04-01 2010-10-21 Genentech, Inc. Anti-fcrh5 antibodies and immunoconjugates and methods of use
BRPI1014089A2 (en) 2009-04-02 2016-04-19 Roche Glycart Ag multispecific antibodies comprising full length antibodies and single chain fab fragments
CA2759506A1 (en) * 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
AU2010249787A1 (en) 2009-05-20 2011-12-22 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
RU2012101999A (en) 2009-06-22 2013-07-27 МЕДИММЬЮН, ЭлЭлСи Fc RECOMBINED SITES FOR SITE-SPECIFIC CONJUGATION
BR112012002083A2 (en) 2009-07-31 2016-11-08 Genentech Inc tumor metastasis inhibition
CA2772715C (en) 2009-09-02 2019-03-26 Genentech, Inc. Mutant smoothened and methods of using the same
SG10201408401RA (en) 2009-09-16 2015-01-29 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US8759491B2 (en) * 2009-10-19 2014-06-24 Genentech, Inc. Modulators of hepatocyte growth factor activator
MX2012004647A (en) 2009-10-22 2012-06-19 Genentech Inc Anti-hepsin antibodies and methods using same.
CN102711826B (en) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 For the method and composition that the HEPSIN for regulating and controlling macrophage-stimulating albumen is activated
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
BR112012010153B1 (en) 2009-11-05 2022-05-03 Genentech, Inc Method of producing an antibody
CA2781887C (en) 2009-11-30 2018-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US8486397B2 (en) 2009-12-11 2013-07-16 Genentech, Inc. Anti-VEGF-C antibodies and methods using same
AU2010336485B2 (en) 2009-12-23 2015-03-26 Genentech, Inc. Anti-Bv8 antibodies and uses thereof
US20110159588A1 (en) 2009-12-30 2011-06-30 Kui Lin Methods for Modulating a PDGF-AA Mediated Biological Response
EP2538981B1 (en) 2010-02-23 2017-12-20 F. Hoffmann-La Roche AG Compositions and methods for the diagnosis and treatment of tumor
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
MX346731B (en) 2010-04-23 2017-03-30 Genentech Inc * Production of heteromultimeric proteins.
MA34291B1 (en) 2010-05-03 2013-06-01 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
NZ602840A (en) 2010-06-03 2014-11-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
WO2012021786A2 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
ES2920140T3 (en) 2010-08-31 2022-08-01 Theraclone Sciences Inc Human immunodeficiency virus (HIV) neutralizing antibodies
US9085621B2 (en) 2010-09-10 2015-07-21 Apexigen, Inc. Anti-IL-1β antibodies
US8481680B2 (en) 2010-10-05 2013-07-09 Genentech, Inc. Mutant smoothened and methods of using the same
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
AR085138A1 (en) 2011-02-04 2013-09-11 Genentech Inc Fc VARIATIONS AND METHODS FOR PRODUCTION
EP2675478A4 (en) 2011-02-14 2015-06-10 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
US8753634B2 (en) 2011-03-03 2014-06-17 Apexigen, Inc. Anti-IL-6 receptor antibodies and methods of use
BR112013023576A2 (en) 2011-03-15 2016-12-06 Theraclone Sciences Inc compositions and methods for influenza therapy and diagnosis
CN103635488B (en) 2011-04-29 2016-12-14 埃派斯进有限公司 Anti-CD 40 antibodies and using method thereof
CA2835203A1 (en) 2011-05-09 2012-11-15 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
MX2014001736A (en) 2011-08-17 2014-03-31 Genentech Inc Inhibition of angiogenesis in refractory tumors.
WO2013033069A1 (en) 2011-08-30 2013-03-07 Theraclone Sciences, Inc. Human rhinovirus (hrv) antibodies
ES2806146T3 (en) 2011-09-22 2021-02-16 Amgen Inc CD27L antigen-binding proteins
MX2014004991A (en) 2011-10-28 2014-05-22 Genentech Inc Therapeutic combinations and methods of treating melanoma.
EP2785742B1 (en) 2011-11-02 2020-01-08 Apexigen, Inc. Anti-kdr antibodies and methods of use
EA201490974A1 (en) 2011-11-16 2014-09-30 Эмджен Инк. METHODS OF TREATMENT OF DISORDERS ASSOCIATED WITH DELIVERY MUTANT VIII EPIDERMAL GROWTH FACTOR
JP6218746B2 (en) 2011-12-08 2017-10-25 バイオテスト・アクチエンゲゼルシヤフト Use of immune complexes targeting CD138
EP3539982A3 (en) 2011-12-23 2020-01-15 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6684490B2 (en) 2012-01-09 2020-04-22 ザ・スクリップス・リサーチ・インスティテュート Ultralong complementarity determining regions and uses thereof
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
SG11201405553YA (en) 2012-03-08 2014-11-27 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
AR090549A1 (en) 2012-03-30 2014-11-19 Genentech Inc ANTI-LGR5 AND IMMUNOCATE PLAYERS
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
KR20150006000A (en) 2012-05-01 2015-01-15 제넨테크, 인크. Anti-pmel17 antibodies and immunoconjugates
UY34813A (en) 2012-05-18 2013-11-29 Amgen Inc ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER
CN104395339A (en) 2012-06-27 2015-03-04 弗·哈夫曼-拉罗切有限公司 Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
RU2015100656A (en) 2012-06-27 2016-08-20 Ф. Хоффманн-Ля Рош Аг METHOD FOR PRODUCING ANTIBODY FC-FRAGMENT CONNECTING, INCLUDING AT LEAST ONE CONNECTING GROUP, WHICH SPECIALLY RELATED TO THE TARGET, AND THEIR APPLICATION
CA2880701A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
PL2900676T3 (en) 2012-09-26 2019-06-28 Immunogen, Inc. Improved method for the acylation of maytansinol
KR102270618B1 (en) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 Anti-cd40 antibodies and methods of use
TW201425336A (en) 2012-12-07 2014-07-01 Amgen Inc BCMA antigen binding proteins
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP3299391B1 (en) 2013-03-14 2019-12-04 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
AU2014273966B2 (en) 2013-05-30 2017-08-31 Kiniksa Pharmaceuticals, Ltd. Oncostatin M receptor antigen binding proteins
EP3013365B1 (en) 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CN111518199A (en) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 Humanized antibodies with ultralong complementarity determining regions
EP3738611A1 (en) 2013-07-31 2020-11-18 BioNTech AG Diagnosis and therapy of cancer involving cancer stem cells
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
KR20160055253A (en) 2013-09-12 2016-05-17 할로자임, 아이엔씨 Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
RU2016109247A (en) 2013-09-17 2017-10-19 Дженентек, Инк. WAYS OF APPLICATION OF ANTIBODIES TO LGR5
CN105813654B (en) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) TEM8 antibody and application thereof
WO2015069922A2 (en) 2013-11-06 2015-05-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
EP3080164B1 (en) 2013-12-13 2019-01-16 Genentech, Inc. Anti-cd33 antibodies and immunoconjugates
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015109180A2 (en) 2014-01-16 2015-07-23 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3096797A1 (en) 2014-01-24 2016-11-30 F. Hoffmann-La Roche AG Methods of using anti-steap1 antibodies and immunoconjugates
EP3102197B1 (en) 2014-02-04 2018-08-29 Genentech, Inc. Mutant smoothened and methods of using the same
CN106415244B (en) 2014-03-27 2020-04-24 中央研究院 Reactive marker compounds and uses thereof
CN106232139A (en) 2014-04-11 2016-12-14 免疫医疗有限责任公司 Bispecific HER2 antibody
EP3140392B1 (en) 2014-05-06 2023-07-26 F. Hoffmann-La Roche AG Production of heteromultimeric proteins using mammalian cells
JP2017522861A (en) 2014-05-22 2017-08-17 ジェネンテック， インコーポレイテッド Anti-GPC3 antibody and immunoconjugate
CA2950440A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP6894239B2 (en) 2014-05-27 2021-06-30 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Compositions and methods for universal glycoforms for enhanced antibody efficacy
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
TWI732738B (en) 2014-05-28 2021-07-11 中央研究院 Anti-tnf-alpha glycoantibodies and uses thereof
KR20170040249A (en) 2014-08-12 2017-04-12 노파르티스 아게 Anti-cdh6 antibody drug conjugates
BR112017003835A2 (en) 2014-08-28 2018-04-10 Bioatla Llc chimeric antigen receptor, expression vector, genetically engineered cytotoxic cell, pharmaceutical composition, and methods for producing a chimeric antigen receptor and for treating a disease in an individual.
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
BR112017004631A2 (en) 2014-09-12 2018-01-30 Genentech, Inc. antibody, nucleic acid, host cell, antibody production method, immunoconjugate, pharmaceutical formulation, methods of treatment, cell proliferation inhibition and human her2 detection and method for cancer detection
CN113698488A (en) 2014-09-12 2021-11-26 基因泰克公司 anti-B7-H4 antibodies and immunoconjugates
US9751946B2 (en) 2014-09-12 2017-09-05 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
SI3262071T1 (en) 2014-09-23 2020-07-31 F. Hoffmann-La Roche Ag Method of using anti-cd79b immunoconjugates
EP3200829B1 (en) 2014-10-01 2023-12-06 Medimmune, LLC Method of conjugating a polypeptide
WO2016073789A2 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
CN107001482B (en) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 Multispecific antibodies
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
CN107430127B (en) 2015-01-24 2020-08-28 中央研究院 Cancer markers and methods of use thereof
WO2016118191A1 (en) 2015-01-24 2016-07-28 Academia Sinica Novel glycan conjugates and methods of use thereof
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
US10780179B2 (en) 2015-03-18 2020-09-22 Immunobiochem Corporation Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
AU2016252773B2 (en) 2015-04-24 2022-06-02 Genentech, Inc. Multispecific antigen-binding proteins
EP3845557B1 (en) 2015-06-12 2023-08-02 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
JP6821688B2 (en) 2015-10-09 2021-01-27 ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． Chimeric antigen receptor and usage
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
CN108495653A (en) 2016-01-27 2018-09-04 免疫医疗有限责任公司 The method for being used to prepare glycosylation pattern antibody with definition
JP2019515876A (en) 2016-03-08 2019-06-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Methods for module synthesis of N-glycans and their arrays
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
MX2018012418A (en) 2016-04-15 2019-07-10 Bioatla Llc Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof.
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CA3022840A1 (en) 2016-05-05 2017-11-09 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
HRP20221298T1 (en) 2016-05-13 2022-12-23 Bioatla, Inc. Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
WO2018045325A1 (en) 2016-09-02 2018-03-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
EP4015532A1 (en) 2016-11-21 2022-06-22 cureab GmbH Anti-gp73 antibodies and immunoconjugates
AU2017382883A1 (en) 2016-12-21 2019-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
CA3096798A1 (en) 2017-01-09 2018-07-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
JOP20190187A1 (en) 2017-02-03 2019-08-01 Novartis Ag Anti-ccr7 antibody drug conjugates
WO2018175988A1 (en) 2017-03-24 2018-09-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd33 immunotherapy
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AU2018268970A1 (en) 2017-05-19 2019-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
AR111963A1 (en) 2017-05-26 2019-09-04 Univ California METHOD AND MOLECULES
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human mesothelin antibodies and uses in cancer therapy
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019028051A1 (en) 2017-07-31 2019-02-07 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
US10543263B2 (en) 2017-10-16 2020-01-28 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD22 immunotherapy
WO2019126464A2 (en) 2017-12-20 2019-06-27 Lentigen Technology, Inc. Compositions and methods for treating hiv/aids with immunotherapy
CA3105694A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
CN112585163A (en) 2018-08-08 2021-03-30 美国政府(由卫生和人类服务部的部长所代表) High-affinity monoclonal antibody targeting glypican-2 and application thereof
WO2020061498A1 (en) 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
AU2019350865A1 (en) 2018-09-26 2021-04-29 Lentigen Technology, Inc. Compositions and methods for treating cancer with Anti-CD19/CD22 immunotherapy
US11103533B2 (en) 2018-11-30 2021-08-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD38 immunotherapy
CA3119798A1 (en) 2018-12-06 2020-06-11 Genentech, Inc. Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
AU2020206308A1 (en) 2019-01-08 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
AU2020212534A1 (en) 2019-01-22 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2020181164A1 (en) 2019-03-06 2020-09-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
EP3941526A1 (en) 2019-03-19 2022-01-26 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
KR20220007136A (en) 2019-05-14 2022-01-18 제넨테크, 인크. Methods of Use of Anti-CD79b Immunoconjugates to Treat Follicular Lymphoma
US11052112B2 (en) 2019-05-30 2021-07-06 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-BCMA immunotherapy
MX2022000174A (en) 2019-07-02 2022-05-20 Us Health Monoclonal antibodies that bind egfrviii and their use.
WO2021010326A1 (en) 2019-07-12 2021-01-21 中外製薬株式会社 Anti-mutation type fgfr3 antibody and use therefor
BR112022007216A2 (en) 2019-10-18 2022-08-23 Genentech Inc METHODS FOR TREATMENT OF DIFFUSE LYMPHOMA, KIT AND IMMUNOCONJUGATE
US20220380471A1 (en) 2019-10-22 2022-12-01 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting b7-h3 (cd276) for treating multiple solid tumors
AU2020402752A1 (en) 2019-12-12 2022-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates specific for CD276 and uses thereof
IL297541A (en) 2020-04-24 2022-12-01 Genentech Inc Methods of using anti-cd79b immunoconjugates
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CA3171101A1 (en) 2020-06-22 2021-12-30 Dina SCHNEIDER Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
KR20230069211A (en) 2020-09-18 2023-05-18 아라리스 바이오테크 아게 Transglutaminase conjugation method using an amino acid-based linker
EP4232095A1 (en) 2020-10-25 2023-08-30 Araris Biotech AG Means and methods for producing antibody-linker conjugates
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
EP4240397A1 (en) 2020-11-05 2023-09-13 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
BR112023023622A2 (en) 2021-05-12 2024-02-06 Genentech Inc METHODS TO TREAT DIFFUSE LYMPHOMA, KITS, IMMUNOCONJUGATES, POLATUZUMABE VEDOTIN AND IMMUNOCONJUGATE FOR USE
CN117396513A (en) 2021-05-28 2024-01-12 葛兰素史密斯克莱知识产权发展有限公司 Combination therapy for the treatment of cancer
AU2022291120A1 (en) 2021-06-09 2023-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
US11807685B2 (en) 2021-08-05 2023-11-07 The Uab Research Foundation Anti-CD47 antibody and uses thereof
WO2023019092A1 (en) 2021-08-07 2023-02-16 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
US20240075142A1 (en) 2022-08-26 2024-03-07 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) * 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4137230A (en) * 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) * 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) * 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566586A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation

Also Published As

Publication number Publication date
EP0021178A1 (en) 1981-01-07
ATE5885T1 (en) 1984-02-15
JPS55164685A (en) 1980-12-22
EP0021178B1 (en) 1984-01-18
US4317821A (en) 1982-03-02
DE3066149D1 (en) 1984-02-23

Similar Documents

Publication Publication Date Title
CA1135260A (en) Maytansinoids, their production and use
US4308268A (en) Maytansinoids, pharmaceutical compositions thereof and method of use thereof
CA1133478A (en) Maytansinoids, their production and use
US4256746A (en) Dechloromaytansinoids, their pharmaceutical compositions and method of use
US4309428A (en) Maytansinoids
US4260608A (en) Maytansinoids, pharmaceutical compositions thereof and methods of use thereof
CA2617953C (en) Method of acylating maytansinol with chiral amino acids
US4424219A (en) 9-Thiomaytansinoids and their pharmaceutical compositions and use
US4308269A (en) Maytansinoids, pharmaceutical compositions thereof and method of use thereof
Kupchan et al. Tumor inhibitors. 124. Structural requirements for antileukemic activity among the naturally occurring and semisynthetic maytansinoids
US4190580A (en) Optically active maytansinoids and maytansinoid production method
CA1102798A (en) Production of maytansinoids
US4361650A (en) Fermentation process of preparing demethyl maytansinoids
KR970011385B1 (en) Disulfur analogs of ll-e33288 antitumor agents
US4264596A (en) Maytansinoids, pharmaceutical compositions thereof and method of use thereof
CA1133901A (en) Dechloromaytansinoids, their production and use
US4263294A (en) Maytansinoids, pharmaceutical compositions thereof and method of use thereof
CA1144096A (en) Demethyl maytansinoids
IE47252B1 (en) Antitumor anthracycline antibiotics
CA1082180A (en) Oxazolidinedione derivatives of vinca alkaloids
KR940009795B1 (en) Process for preparing 2&#39;-substituted-4-deoxythiazolo£5,4-c|rifamycin sv derivatives
USRE30561E (en) Vinca alkaloid intermediates
USRE30560E (en) Oxazolidinedione derivatives of Vinca alkaloids
KR810000812B1 (en) Process for preparing new rifamycin derivatives
KR950010086B1 (en) New 2&#39;-substituted-4-deoxythiazolo(5,4-c)rifamycin sv derivatives

Legal Events

Date Code Title Description
MKEX Expiry